Monopar Therapeutics closed at $72.81 on Nov 4, up 4.18%, 41.2% below its 52-week closing high. Volume of 189.7K shares was 1.33× its 20-day average (above normal).
Split-adjusted performance: -8.5% over one month, +14.0% over six months, -13.3% over one year.
Short interest was 1.1M shares at the Oct 15 settlement, up 3.9% from the prior report (23.3% of float, 7.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MNPRMonopar Therapeutics | $72.81 | +4.18% | +14.0% | — | — | — | $488.7M | |
| ARVNArvinas | $7.42 | +4.65% | −27.7% | +1014.7% | 67.8% | 52.2 | $485.2M | Compare |
| EOLSEvolus | $7.47 | +1.36% | +18.2% | +21.2% | −9.6% | — | $493.4M | Compare |
| AQSTAquestive Therapeutics | $3.80 | −2.06% | −10.2% | +38.1% | −165.5% | — | $476.9M | Compare |
| GYREGyre Therapeutics | $4.44 | 0.00% | −44.8% | −2.1% | −40.1% | — | $470.8M | Compare |
| CTMXCytomX Therapeutics | $2.35 | +7.80% | −43.1% | −92.4% | −1457.4% | — | $512.1M | Compare |
| CBIOCrescent Biopharma | $13.82 | +5.82% | −23.5% | — | — | — | $513.4M | Compare |
| FTHFaeth Therapeutics | $19.99 | +1.73% | — | — | — | — | $516.6M | Compare |
| STTKShattuck Labs | $5.15 | −5.85% | −22.9% | — | — | — | $516.9M | Compare |
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
